Neuronostatin - a Glucagonotropic Agent in Humans?

Launched by UNIVERSITY HOSPITAL, GENTOFTE, COPENHAGEN · Nov 15, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a hormone called neuronostatin-13 (NST) to understand how it affects glucagon secretion in people. Glucagon is a hormone that helps raise blood sugar levels, which is important for people who have conditions like diabetes. The researchers want to see how NST works at different blood sugar levels, specifically during times when blood sugar is normal, high, or low.

To participate in this study, individuals must be men aged between 65 and 74, have normal blood sugar levels and hemoglobin, and a healthy body weight. They shouldn’t have diabetes, liver disease, or any conditions that could affect the study results. Participants will attend six days of testing, where they will receive either NST or a placebo (a harmless saline solution) while their blood sugar levels are carefully controlled. This study can help researchers learn more about how NST might be used in managing blood sugar levels in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Normal haemoglobin \>8.3 mmol/l
• • Normal fasting plasma glucose below 7 mmol/l
• • Normal HbA1C \<42 mmol/mol (6%)
• • Body mass index (BMI) 18.5-27 kg/m2
• • Oral and written informed consent
• Exclusion Criteria:
• • Diabetes
• • Treatment with drugs that might interfere with glucose metabolism within a month prior to the research study
• • Treatment with any medication that cannot be paused for 12 hours
• • Known liver disease and/or alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>2 × normal values
• • Nephropathy (eGFR \<60 ml/min and/or albuminuria)
• • Any condition that the investigator feels would interfere with trial participation